Open AccessTreatment of spontaneous osteonecrosis of the knee by daily teriparatide
Author(s) -
Akira Horikawa,
Naohisa Miyakoshi,
Michio Hongo,
Yuji Kasukawa,
Yasuhiro Shimada,
Hiroyuki Kodama,
Akihisa Sano
Publication year - 2020
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000018989
Subject(s) - teriparatide , medicine , magnetic resonance imaging , visual analogue scale , knee pain , surgery , osteoporosis , osteoarthritis , radiology , bone mineral , pathology , alternative medicine
Rationale: Although the treatment of femoral head necrosis has already been established with the adoption of daily teriparatide, a clear consensus on the treatment of spontaneous osteonecrosis of the knee (SONK) has yet to be reached. Therefore, we focused on the treatment of SONK with daily teriparatide administration (20 μg, subcutaneous) and confirmed its effects to determine whether it is a valid option. Patients’ concerns: Three osteoporotic patients who were diagnosed with SONK complained of knee pain. Diagnosis: SONK was diagnosed on magnetic resonance imaging in all cases. Interventions: All patients took daily teriparatide as a treatment for SONK. Outcomes: There was a significant and dramatic reduction in the visual analog scale score 1 month after treatment. After 6 months of treatment, the sizes of the affected SONK lesions were smaller than in the initial phase, and plain X-rays showed no further signs of progression. Lessons: Daily teriparatide might be an effective treatment for SONK.